Avicanna General Meeting
19 juin 2024 17h30 HE
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
19 juin 2024 07h30 HE
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna to Present at the Life Science Investor Forum June 20th, 2024
18 juin 2024 07h45 HE
|
Avicanna Inc.
TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
14 mai 2024 07h35 HE
|
Avicanna Inc.
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of Trunerox™...
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
13 mai 2024 07h30 HE
|
Avicanna Inc.
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. ...
Avicanna Announces Closing of Non-brokered Private Placement
18 avr. 2024 17h00 HE
|
Avicanna Inc.
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
10 avr. 2024 08h37 HE
|
Avicanna Inc.
TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna Reports Full Year 2023 Audited Financial Results
02 avr. 2024 07h30 HE
|
Avicanna Inc.
$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna...
Avicanna anuncia el lanzamiento en Canadá de una formulación de su propiedad con un 10% de CBD (sin THC)
28 mars 2024 07h30 HE
|
Avicanna Inc.
La formulación oral con un 10% de CBD (sin THC) se comercializa como RHO Phyto Micro Drop 100 en Canadá. RHO Phyto Micro Drop 100 está disponible exclusivamente en MyMedi.ca. TORONTO, March 28,...
Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation
27 mars 2024 08h02 HE
|
Avicanna Inc.
The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE...